A meta-analysis on sodium–glucose cotransporter-2 (SGLT2) inhibitors and LVRR included 13 trials and a total of 1251 patients with T2DM and/or HF, which found that SGLT2 inhibitors significantly improve LVEF, LV mass index, LVESV index and E-wave deceleration time during follow-up [30]. Here, SLC5A2 is linked to hydrops fetalis.